With 0.61 million shares changed hands, the volume of the stock remained heavier than its average volume of 0.33 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $3.6276 whereas the lowest price it dropped to was $3.0. The 52-week range on RZLT shows that it touched its highest point at $3.49 and its lowest point at $0.72 during that stretch. It currently has a 1-year price target of $9.50. Beta for the stock currently stands at 1.26.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of RZLT was up-trending over the past week, with a rise of 36.00%, but this was up by 91.01% over a month. Three-month performance surged to 236.63% while six-month performance rose 292.88%. The stock gained 94.29% in the past year, while it has gained 242.57% so far this year. A look at the trailing 12-month EPS for RZLT yields -1.11 with Next year EPS estimates of -0.72. For the next quarter, that number is -0.28. This implies an EPS growth rate of -9.50% for this year and 34.90% for next year.
Float and Shares Shorts:
At present, 36.83 million RZLT shares are outstanding with a float of 28.19 million shares on hand for trading. On 2024-03-28, short shares totaled 0.25 million, which was 64.0 higher than short shares on 1709164800. In addition to Mr. Nevan Charles Elam J.D. as the firm’s Founder, CEO & Acting Chairman of the Board, Dr. Brian Kenneth Roberts M.D. serves as its Chief Medical Officer.
Institutional Ownership:
Through their ownership of 0.77723 of RZLT’s outstanding shares, institutional investors have minority control over the company.
An Overview of Recent Financials:
Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on 2023-12-31, RZLT reported revenue of $0.0 and operating income of -$15194000.0. The EBITDA in the recently reported quarter was -$15166000.0 and diluted EPS was -$0.27.
Analysts Ratings:
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for RZLT since 0 analysts follow the stock currently. In the same way, a target price assigned to a stock can also reveal much about its potential.
Dividends & Yield:
In terms of dividends, RZLT has a current ratio of $––, which is $–– over the trailing 12-months, while a dividend of $–– is likely to be paid on average over the next five years. Dividend yield is another indicator that appeals to many investors, and RZLT currently yields $0.00. In the past year, RZLT’s dividend yield has been $0.00, but when looking at the stock over the past five years, its yield has been $–. Accordingly, RZLT has a current buyback yield of $0.00. This was $0.00 for the TTM, and it was $– for the past five years.
